Ralf Bundschuh

The Ohio State University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index4.7kcitations265works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA and protein synthesis mechanisms(88), RNA Research and Splicing(60), RNA modifications and cancer(48), Genomics and Phylogenetic Studies(42), DNA and Nucleic Acid Chemistry(21)

Publications265 total

Supplementary Figure S1 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Data from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S8 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S5 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S6 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S3 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S7 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S10 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S2 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S4 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
Clinical Cancer Research·2025
The structural effects of indel polymorphisms outside the binding site on RNA-protein interactions are shaped by selection
PLoS Computational Biology·2025Open Access
PYM1 limits non-canonical Exon Junction Complex occupancy in a gene architecture dependent manner to tune mRNA expression
Nature Communications·2025· 1 citedOpen Access
Free energy spectroscopy reveals the mechanistic landscape of chromatin compaction
2025Open Access
FINAL TECHNICAL REPORT: Energy Exchange in Dynamic DNA-Metal Hybrid Materials
2025
PYM1 limits non-canonical Exon Junction Complex occupancy in a gene architecture dependent manner to tune mRNA expression
2025Open Access
BPS2025 - Revealing the energetics of chromatin compaction with DNA nanotechnology
Biophysical Journal·2025
BPS2025 - Revealing the energetics of chromatin compaction with DNA nanotechnology
Biophysical Journal·2025
Identification of leader–trailer helices of precursor ribosomal RNA in all phyla of bacteria and archaea
RNA·2024Open Access
A-to-I Editing Is Subtype-Specific in Non-Hodgkin Lymphomas
Genes·2024· 1 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Pearlly S. Yan(13), Terence Hwa(6), Guido Marcucci(5), David Frankhouser(5), John C. Byrd(5), Michael G. Poirier(5), Elan Shatoff(4), Kurt Fredrick(4), John Curfman(4), Deedra Nicolet(3), Klaus H. Metzeler(3), Jessica Kohlschmidt(3), Krzysztof Mrózek(3), Susan P. Whitman(3), Sebastian Schwind(3), Bayard L. Powell(3), Jonathan E. Kolitz(3), Ramiro Garzon(3), Michael A. Caligiuri(3), Richard M. Stone(3)